WebSite > Shenzhen Nexcon Pharmatechs Ltd.

Shenzhen Nexcon Pharmatechs Ltd.

  • Company Name Shenzhen Nexcon Pharmatechs Ltd.
  • Tel -+86-0755-89396905
  • Email admin@nexconn.com
  • WebSite 
  • CB Index 58
  •       1. Core Business: Shenzhen Nexconn Pharmatechs Ltd. specializes in the?R&D, contract manufacturing, and global sourcing of intermediates and specialty chemicals. Over its 19-year development, the company has demonstrated a strong commitment to innovation, launching dozens of new products annually to meet diverse industrial and pharmaceutical needs. 2. Key Strengths: ① Quality Assurance: Certified under?GMP and ISO standards, the company prioritizes stringent quality control and operational excellence. ② Comprehensive Service: Supported by a robust after-sales service system, Nexconn ensures year-round technical assistance and customer support. ③ Product Portfolio: With over?10,000 listed products, the company caters to a wide range of sectors, emphasizing reliability and adaptability. 3. Innovation & Mission: Guided by the vision "Innovation to Bring Healthy Life," Nexconn integrates cutting-edge research with sustainable practices to advance health and industrial solutions. Its focus on technological development and collaborative partnerships underscores its role as a trusted partner in global supply chains. 4. Commitment: Nexconn thrives on mutual benefit and long-term cooperation, delivering?fast, reliable, and customized solutions?to clients worldwide.
Shenzhen Nexcon Pharmatechs Ltd. Product List
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Product Name FEPN
  • MF 
  • CAS 
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Product Name H-Aib-OBzl
  • MF C11H16ClNO2
  • CAS 60421-20-7
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •